The China diabetes market was valued at USD 5.18 Billion in 2025 and is expected to grow at a CAGR of 9.50%, reaching USD 12.84 Billion by 2035. The market growth is driven by increasing urbanization, growing health awareness, and a rising aging population with sedentary lifestyles across the region. Expanding access to digital health platforms and wearable glucose monitoring devices is boosting patient engagement. Government initiatives for early diagnosis and disease management, along with technological advancements in insulin delivery, are projected to support market growth over the forecast period.
Base Year
Historical Period
Forecast Period
According to Yu-Chang Zhou et al., 2025, an estimated 233 million people in China were living with diabetes in 2023, with prevalence rising by nearly 50% since 2005, significantly accelerating growth in the Chinese market.
In December 2023, Hua Medicine’s dorzagliatin was added to China’s NRDL, improving access to innovative Type 2 diabetes treatment. This key development is expected to accelerate growth in the China diabetes market by enhancing affordability and uptake.
One of the major market drivers is the rising focus on renal-impaired diabetic patients. For instance, in January 2025, Poxel secured a Chinese patent for Imeglimin, addressing this large subpopulation and accelerating market growth.
Compound Annual Growth Rate
9.5%
Value in USD Billion
2026-2035
*this image is indicative*
Diabetes has become a major public health concern due to changing lifestyles, increasing obesity, and aging populations. It poses serious health risks and economic burdens, driving the demand for effective management and treatment solutions. In China, the diabetes market is expanding rapidly, supported by government initiatives, rising awareness, and improved healthcare infrastructure. The growing prevalence of both Type 1 and Type 2 diabetes has led to increased adoption of advanced diagnostics, medications, and digital health tools. The market is poised to reach USD 12.84 Billion by 2035, reflecting strong investment and innovation across the country’s healthcare sector.
Adoption of Innovative Insulin Delivery Systems to Accelerate the Growth in the Market
The advancement of intelligent insulin delivery systems is a key growth driver in the market. For instance, in May 2025, researchers at Zhejiang University, led by Professor Zhen Gu, developed “i-crystal,” a smart insulin delivery platform published in Nature Nanotechnology. This system features a glucose-responsive coating that releases insulin based on blood sugar and ketone levels, offering precise, long-term glycemic control. Early animal studies demonstrated effectiveness lasting several weeks, significantly reducing injection frequency. Such innovations are expected to enhance diabetes care in China, contributing to robust market growth.
The market is experiencing key trends such as the increasing approval of advanced diabetes therapies and the growing integration of genetic diagnostics.
Rising Approval of Advanced Diabetes Therapies to Boost Market Value in China
The growing approval of innovative diabetes treatments is significantly shaping the Chinese diabetes market. In May 2024, Eli Lilly's tirzepatide, the active compound in Mounjaro, received regulatory approval in China, marking a key development in the country's diabetes care landscape. This milestone underscores intensifying competition among global pharmaceutical giants and reflects China’s expanding access to cutting-edge GLP-1 therapies. As demand for effective diabetes solutions continues to rise, such advancements are poised to accelerate the market's long-term growth trajectory.
Genetic Diagnostics Integration to Strengthen China Diabetes Market Demand
The market is witnessing a significant trend toward the integration of advanced genetic diagnostics to improve diabetes classification. In June 2025, a landmark clinical trial involving 3,000 participants across 80 hospitals was launched, applying a Chinese-specific genetic risk score to differentiate between type 1 and type 2 diabetes. This initiative, driven by concerns over frequent misdiagnosis, aims to enable earlier and more accurate treatment. As precision diagnostics gain traction, this trend is expected to accelerate market expansion in the coming years.
Type II Diabetes to Lead the Market Based on Type
There are two primary types of diabetes, including Type I and Type II, each requiring distinct treatment approaches. Among these, Type II diabetes is expected to dominate the diabetes market in China due to its significantly higher prevalence and the increasing burden of related complications such as cardiovascular and kidney diseases. Additionally, in June 2023, China’s National Medical Products Administration approved Xigduo XR, a once-daily fixed-dose combination of an SGLT2 inhibitor (dapagliflozin) and metformin extended-release, specifically for adults with Type II diabetes. This innovative treatment addresses both glycemic control and medication adherence challenges, which remain critical issues for over 129 million individuals living with Type II diabetes in China. As a result, the demand for convenient, effective, and integrated therapies is expected to further propel the growth of this segment.
The key features of the market report comprise clinical trials analysis, grants analysis, patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Abbott is a leading global healthcare company with a strong presence in the diabetes care market. Its portfolio includes advanced glucose monitoring products such as the FreeStyle Optium range, designed for both hospital and personal use. While Abbott has a broad international footprint, it remains actively engaged in advancing diabetes care across Asia, including China, by offering innovative and accessible solutions that support effective disease management and improved patient outcomes.
Medtronic is a global leader in medical technology, offering advanced solutions in diabetes care. Its MiniMed™ 780G system, an automated insulin delivery device, is designed to simplify glucose management by adjusting insulin based on real-time needs. Alongside this, the InPen™ smart insulin pen supports flexible, multiple daily injection therapy. While not specific to China in recent news, Medtronic continues to strengthen its presence in the global diabetes market by delivering innovative, patient-centric technologies for Type 1 diabetes management.
Sanofi has been a global leader in diabetes care for over a century, consistently advancing treatment standards through innovative medicines, education programs, and digital health solutions. With a strong portfolio including insulin therapies and connected devices, Sanofi focuses on holistic diabetes management. The company remains actively involved in addressing the global diabetes burden, emphasizing access to care, digital tools, and support programs to improve outcomes for people living with diabetes.
Novo Nordisk, a leading Danish pharmaceutical company specializing in diabetes care, has strengthened its presence in the market with the recent regulatory approval of Awiqli, the world’s first weekly insulin icodec injection, for the treatment of type 2 diabetes in adults. The company is also advancing IcoSema, a combination of insulin icodec and Semaglutide, currently in Phase III clinical trials in China. These innovations reinforce Novo Nordisk's commitment to expanding advanced diabetes therapies in the region.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market include Eli Lilly and Company, Bristol-Myers Squibb Co., Pfizer Inc., Merck KGaA, Johnson & Johnson Innovation Inc., AstraZeneca plc, Boehringer Ingelheim, Novartis AG and Teva Pharmaceuticals.
Market Breakup by Type
Market Breakup by Treatment
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Upto 15% Off
USD
$3099 $2789
$1999 $1799
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share